HLA-DQB1 alleles as genetic modifiers in β-thalassemia major: association with clinical heterogeneity
Journal of Hematopathology · 02.06.2026 · 19 (1)
DOI: 10.1007/s12308-026-00698-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hematopathology, online erschienen am 02.06.2026. Verfasst von Amel Mahmoud Kamal Eldin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pathology, Faculty of Medicine, Minia University, El-Minia, Egypt. Hauptthemen laut MEDLINE: HLA-DQ beta-Chains, beta-Thalassemia, Alleles. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Clinical expression among children with transfusion-dependent β-thalassemia major varies substantially, and this heterogeneity is not fully explained by HBB mutations alone. We evaluated whether HLA-DQB1 alleles were associated with case status in a pediatric case-control cohort and whether selected alleles correlated with hematologic and hemoglobin fraction profiles among affected children. METHODS: This single-center case-control study included 45 children with transfusion-dependent β-thalassemia major and 45 age- and sex-matched healthy controls. HLA-DQB1 genotyping was performed using a sequence-specific primer real-time PCR assay. Allele frequencies were compared between groups, and within-patient analyses examined associations with pre-transfusion hemoglobin, reticulocyte counts, and hemoglobin fractions. Multivariable and internal-validation analyses were treated as exploratory because of the modest sample size. RESULTS: DQB1 0601 was more frequent in cases than controls (9.7% vs. 2.2%, p = 0.034), whereas the DQB1 03 family (30.1% vs. 45.6%, p = 0.031) and particularly DQB1 0302 (6.5% vs. 26.7%, p < 0.001) were less frequent among cases. After Bonferroni correction for 15 allele comparisons, only DQB1 0302 remained significant. Within the patient group, DQB1 0502/0504 was associated with higher pre-transfusion hemoglobin (p = 0.036), DQB1 0501 with higher reticulocyte counts (p = 0.021), and DQB1 0601 with lower HbA1 and higher HbF (both p ≈ 0.03); these phenotype associations were exploratory and did not survive strict multiplicity correction. In adjusted exploratory models, the direction of association remained similar. CONCLUSION: In this Egyptian cohort, HLA-DQB1 alleles were associated with case status and with selected laboratory features among children with transfusion-dependent β-thalassemia major. These findings should be interpreted as association signals rather than evidence of etiologic susceptibility or causation, and they require validation in larger multi-group cohorts that include non-transfusion-dependent thalassemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pathology, Faculty of Medicine, Minia University, El-Minia, Egypt.
- Department of Rheumatology, Faculty of Medicine, Minia University Hospital, El-Minia, Egypt.
- Department of Internal Medicine, Faculty of Medicine, Minia University, El-Minia, Egypt. hesham.keryakos@mu.edu.eg.
Zitieren
APA
Eldin, A. M. K., Abdelnaem, E. A., Mohamed, N. Z., Mohamed, F. I., Elsayed, M. A., & Keryakos, H. K. H. (2026). HLA-DQB1 alleles as genetic modifiers in β-thalassemia major: association with clinical heterogeneity. Journal of Hematopathology, 19(1). https://doi.org/10.1007/s12308-026-00698-2
Vancouver
Eldin AMK, Abdelnaem EA, Mohamed NZ, Mohamed FI, Elsayed MA, Keryakos HKH. HLA-DQB1 alleles as genetic modifiers in β-thalassemia major: association with clinical heterogeneity. Journal of Hematopathology. 2026;19(1). doi:10.1007/s12308-026-00698-2
BibTeX
@article{Eldin2026,
author = {Eldin, Amel Mahmoud Kamal and Abdelnaem, Emad Allam and Mohamed, Nada Zaki and Mohamed, Faten Ismail and Elsayed, Mostafa Ahmed and Keryakos, Hesham Kamal Habeeb},
title = {HLA-DQB1 alleles as genetic modifiers in β-thalassemia major: association with clinical heterogeneity},
journal = {Journal of Hematopathology},
year = {2026},
volume = {19},
number = {1},
doi = {10.1007/s12308-026-00698-2}
}
EUVIMED